X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11) 11
chemotherapy (9) 9
oncology (9) 9
cancer (6) 6
cancer therapies (6) 6
lung cancer (6) 6
lung cancer, non-small cell (6) 6
metastasis (6) 6
mutation (6) 6
aged (5) 5
care and treatment (5) 5
female (5) 5
humans (5) 5
male (5) 5
middle aged (5) 5
patients (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
apoptosis (4) 4
drug therapy (4) 4
gefitinib (4) 4
lung neoplasms - drug therapy (4) 4
platinum (4) 4
tumors (4) 4
abridged index medicus (3) 3
adenocarcinoma (3) 3
adult (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
double-blind (3) 3
drug administration schedule (3) 3
erlotinib (3) 3
immunotherapy (3) 3
lung neoplasms - mortality (3) 3
lung neoplasms - pathology (3) 3
nivolumab (3) 3
non-small cell lung carcinoma (3) 3
paclitaxel (3) 3
pd-l1 protein (3) 3
pembrolizumab (3) 3
pneumonitis (3) 3
prognosis (3) 3
studies (3) 3
aged, 80 and over (2) 2
analysis (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibody (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
asthma (2) 2
bevacizumab (2) 2
cancer patients (2) 2
carboplatin (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
carcinoma, non-small-cell lung - secondary (2) 2
cell survival (2) 2
combination (2) 2
criteria (2) 2
death (2) 2
disease-free survival (2) 2
docetaxel (2) 2
efficacy (2) 2
epidermal growth factor receptors (2) 2
genetic aspects (2) 2
growth-factor receptor (2) 2
hematology, oncology and palliative medicine (2) 2
immunology (2) 2
japan (2) 2
life sciences (2) 2
ligands (2) 2
lung neoplasms - genetics (2) 2
medical imaging (2) 2
medicine, general & internal (2) 2
metastases (2) 2
multicenter (2) 2
neoplasm staging (2) 2
nsclc (2) 2
open-label (2) 2
paclitaxel - administration & dosage (2) 2
receptor (2) 2
receptor, epidermal growth factor - genetics (2) 2
research (2) 2
safety and security measures (2) 2
survival (2) 2
survival analysis (2) 2
therapy (2) 2
toxicity (2) 2
trial (2) 2
1st-line treatment (1) 1
254-s (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - pathology (1) 1
adherence (1) 1
adult asthma (1) 1
adverse events (1) 1
allergy (1) 1
anaplastic lymphoma kinase - drug effects (1) 1
anaplastic lymphoma kinase - genetics (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a... 
MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | BEVACIZUMAB | CRIZOTINIB | NIVOLUMAB | PACLITAXEL | Genes, erbB-1 - drug effects | Lung Neoplasms - drug therapy | Translocation, Genetic | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - metabolism | Middle Aged | Far East - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Anaplastic Lymphoma Kinase - genetics | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Lung Neoplasms - secondary | Female | Carcinoma, Non-Small-Cell Lung - pathology | Anaplastic Lymphoma Kinase - drug effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Genes, erbB-1 - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Disease-Free Survival | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Slopes | Lung cancer | Oncology | Kinases | Cancer therapies | Metastases | Pembrolizumab | Randomization | Motivation | Platinum | Risk assessment | Population | Translocation | Cell survival | Life expectancy | Epidermal growth factor receptors | Hyperthyroidism | Histology | Hypothyroidism | Survival | Patients | Medical centres | Life span | Interactive systems | PD-L1 protein | Men | Ligands | Tumors | Apoptosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2040 - 2051
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 04/2019, Volume 7, Issue 1, pp. 97 - 6
Background: Immune checkpoint inhibitors (ICIs) have provided more options in the treatment of lung cancer. However, ICIs can cause several unfavorable... 
DIAGNOSIS | CELLS | IMMUNOLOGY | ONCOLOGY | ADVERSE EVENTS | Cancer patients | Care and treatment | Lung cancer | Research | Drug therapy | Health aspects | Cancer | Immunoglobulins | Medical imaging | Cytokines | Laboratories | Melanoma | Arthritis | Family medical history | Patients | Cancer therapies | Chemotherapy | Immunotherapy | Tumors
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2019, Volume 25, Issue 18, pp. 5485 - 5492
Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard... 
CISPLATIN | ONCOLOGY | DOUBLE-BLIND | COMBINATION | PEMETREXED PLUS CARBOPLATIN | EXPRESSION | CHEMOTHERAPY
Journal Article